One of the quintessential examples of harnessing both orthosteric and allosteric drugs to overcome drug resistance is dual-targeting BCR-ABL1, one of the most crucial anti-cancer targets within tyrosine kinase family, for CML treatments. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.